Treating rheumatoid arthritis with tumour necrosis factor alpha blockade
- PMID: 11834544
- PMCID: PMC1122253
- DOI: 10.1136/bmj.324.7333.312
Treating rheumatoid arthritis with tumour necrosis factor alpha blockade
Figures
References
-
- Markenson JA. Worldwide trends in the socio-economic impact and long-term prognosis of rheumatoid arthritis. Sem Arthritis Rheumatism. 1991;21(suppl1):4–12. - PubMed
-
- Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomised, controlled study. Ann Intern Med. 1999;130:478–486. - PubMed
-
- Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. - PubMed
-
- Elliot MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105–1110. - PubMed
-
- Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, et al. Therapeutic efficacy of multiple infusions of anti-tumour necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheumatism. 1998;41:1552–1563. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical